VKH
PVLA

Virtu KCG Holdings’s Palvella Therapeutics PVLA Stock Holding History

Virtu KCG Holdings’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-180
Closed -$20K – 3834
2016
Q4 		$20K Buy
+180
New +$22.3K ﹤0.01% 3232
2016
Q3 		– Sell
-147
Closed -$20K – 3544
2016
Q2 		$20K Buy
+147
New +$22.5K ﹤0.01% 2799
2016
Q1 		– Sell
-183
Closed -$33K – 3792
2015
Q4 		$33K Sell
183
-128
-41% -$21.5K ﹤0.01% 3233
2015
Q3 		$46K Buy
+311
New +$69.4K ﹤0.01% 3011

Other funds holding PVLA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu KCG Holdings's PVLA Position: Q1 2017 in Review

Virtu KCG Holdings sold out of Palvella Therapeutics (PVLA) in Q1 2017, closing a stake of 180 shares — an estimated $20K sold.

Virtu KCG Holdings first reported a position in PVLA in Q3 2015 and held it in 4 quarters. The position peaked at $46K in Q3 2015. 27 funds tracked by Wall St. Rank hold PVLA as of Q1 2017.

  • Virtu KCG Holdings reported no remaining Palvella Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Virtu KCG Holdings sold 180 Palvella Therapeutics shares in Q1 2017, an estimated $20K.
  • Virtu KCG Holdings first reported a position in Palvella Therapeutics in Q3 2015 and held it in 4 quarters.
  • Virtu KCG Holdings's Palvella Therapeutics position peaked at $46K in Q3 2015.
  • 27 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2017.

Based on Virtu KCG Holdings's 13F filing for Q1 2017, filed 12 May 2017.